

FY2022 NTAP Payments

Drug-Generic	Drug-Brand	Newness Start Date	FDA Approval Date for NTAP indication	FY2022 IPPS NTAP Status	HCPCS Effective 10/1/21	FY2022 Max Payment	FY2022 ICD-10-PCS Codes
Plazomicin	Zemdri	6/25/2018	06/2018	Continue*	J0291	\$4,083.75	XW033G4, XW043G4
Andexanet alfa	Andexxa	5/3/2018	05/2018	Continue*	J7169	\$18,281.25	XW03372, XW04372
Ultratrace iobenguane Iodine-131	Azedra	5/21/2019	07/2018	Continue	A9590	\$98,150.00	XW033S5, XW043S5
Caplacizumab-yhdp	Cablivi	2/6/2019	02/2019	Continue*	C9047	\$33,215.00	XW013W5, XW033W5, XW043W5
Tagraxofusp-erzs	Elzonris	12/21/2018	12/2018	Continue*	J9269	\$144,116.04	XW033Q5, XW043Q5
Erdafitinib (PO chemotherapy)	Balversa	4/12/2019	04/2019	Continue	C9399 or J8999	\$3,563.23	XW0DXL5
Esketamine (Nasal)	Spravato	3/5/2019	03/2019	Continue*	C9399 or J3490	\$1,014.79	XW097M5
Gilteritinib (PO chemotherapy)	Xospata	11/28/2018	11/2018	Continue*	C9399 or J8999	\$7,312.50	XW0DXV5
Ruxolitinib (PO)	Jakafi	5/24/2019	05/2019	Continue	C9399 or J8499	\$4,475.38	XW0DXT5
Durvalumab	Imfinzi	3/27/2020	03/2020	Continue*	J9173	\$6,875.90	XW03336, XW04336
Atezolizumab	Tecentriq	3/18/2019	03/2019	Continue*	J9022	\$6,875.90	XW033D6, XW043D6
Eculizumab	Soliris	6/27/2019	06/2019	Continue	J1300	\$21,199.75	XW033C6, XW043C6
Cefiderocol	Fetroja	2/24/2020	11/2019	Continue QIDP Indication (cUTI)	J0699	\$7,919.86	XW033A6, XW043A6
Cefiderocol	Fetroja	9/25/2020	09/2020	New QIDP Indication (HABP/VABP)	J0699	\$8,579.84	XW033A6, XW043A6
Fosfomycin	Contepo	TBD		Must meet marketing by 7/1/2022	C9399	\$2,625.00	XW033K5, XW043K5
Omadacycline	Nuzyra	2/1/2019	10/2018	Continue QIDP*	J0121	\$1,552.50	XW033B6, XW043B6
Imipenem/Cilastatin/relebactam	Recarbrio	1/6/2020	07/2019	Continue QIDP Indication (cUTI/cIAI)	J0742	\$3,532.78	XW033U5, XW043U5
Imipenem/Cilastatin/relebactam	Recarbrio	6/4/2020	06/2020	New QIDP Indication (HABP/VABP)	J0742	\$9,577.00	XW033U5, XW043U5
Lefamulin	Xenleta	9/10/2019	08/2019	Continue QIDP	J0691	\$1,275.75	XW03366, XW04366, XW0DX66
Ceftolozane/tazobactam	Zerbaxa	6/3/2019	06/2019	Continue QIDP	J0695	\$1,836.98	XW03396, XW04396
Amivantamab	Rybrevent	5/21/2021	05/2021	New	C9083	\$6,405.89	XW033B7, XW043B7
Lisocabtagene maraleucel	Breyanzi	2/21/2021	02/2021	Denied	Q2054	N/A	XW033N7, XW043N7
Trilaciclib	Cosela	2/12/2021	02/2021	New	J1448	\$5,526.30	XW03377, XW04377
Satralizumab-mwge	Enspryng	8/24/2020	08/2020	Denied	C9399	N/A	XW01397
Idecabtagene vicleucel	Abecma	3/26/2021	03/2021	New	C9081	\$272,675.00	XW033K7, XW043K7
Baricitinib**	Olumiant	11/19/2020	(did not meet FDA approval by 7/1/2021)	Denied	C9399	N/A	XW0DXM6, XW0G7M6, XW0H7M6
Brexucabtagene autoleucel	Tecartus	7/24/2020	07/2020	New	Q2053	\$259,350.00	XW033M7, XW043M7
Remdesivir	Veklury	10/22/2020	10/2020	New	C9399	\$2,028.00	XW033E5, XW043E5
Lurbinectedin	Zepzelca	6/15/2020	06/2020	New	J9223	\$8,622.90	XW03387, XW04387

FY2022 NTAP Payments

Updated: 9/25/2021

*Due to the COVID public health crisis, 2019 MedPar claims data was used to calculate NTAP. Therefore, NTAP agents have received a one year extension that would have otherwise been discontinued for FY22.

**As Baricitinib did not receive FDA approval by 7/1/21, it is not eligible for NTAP for FY22. However, Baricitinib is eligible for the New Covid Technology Add On Payment (NCTAP) under the EUA through the end of the public health emergency.

Disclaimer:

The Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.